

Durham Research Online

Deposited in DRO:

21 October 2016

Version of attached file:

Published Version

Peer-review status of attached file:

Peer-reviewed

Citation for published item:

Lethbridge, N.L. and Chazot, P.L. (2016) 'Ligand autoradiographical quantification of histamine H3 receptor in human dementia with Lewy bodies.', *Pharmacological research*, 113 (Part A). pp. 245-256.

Further information on publisher's website:

<https://doi.org/10.1016/j.phrs.2016.08.034>

Publisher's copyright statement:

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license.

Additional information:

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.



Ligand autoradiographical quantification of histamine H₃ receptor in human dementia with Lewy bodies



Natasha L. Lethbridge, Paul L. Chazot (PhD FBPhS)*

Department of Biosciences, University of Durham, Durham, UK

ARTICLE INFO

Article history:

Received 13 June 2016

Received in revised form 24 August 2016

Accepted 31 August 2016

Available online 31 August 2016

Keywords:

Human

DLB

Psychosis

Globus pallidus

Histamine

H₃R

ABSTRACT

Dementia with Lewy bodies (DLB) is a serious age-dependent human neurodegenerative disease, with multiple debilitating symptoms, including dementia, psychosis and significant motor deficits, but with little or no effective treatments. This comparative ligand autoradiographical study has quantified histamine H₃ receptors (H₃R) in a series of major cortical and basal ganglia structures in human DLB and Alzheimer's (AD) post-mortem cases using the highly selective radioligand, [³H] GSK189254.

In the main, the levels of H₃ receptor were largely preserved in DLB cases when compared with aged-matched controls. However, we provide new evidence showing variable levels in the globus pallidus, and, moreover, raised levels of Pallidum H₃ correlated with positive psychotic symptoms, in particular delusions and visual hallucinations, but not symptoms associated with depression. Furthermore, no correlation was detected for H₃ receptor levels to MMSE or IUPRS symptom severity.

This study suggests that H₃R antagonists have scope for treating the psychotic symptomologies in DLB and other human brain disorders.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Dementia with Lewy bodies (DLB) is the second most prevalent human dementia. This is a seriously debilitating human disease, with multiple prevalent symptoms, including dementia, psychosis (hallucinations and fluctuating consciousness) and significant motor deficits, but with little or no effective treatments [1]. The histaminergic system plays an important role in central nervous system regulation and behaviour through its role as an autoreceptor, regulating the synthesis and release of histamine and as a heteroreceptor, negatively regulating the release of a variety of other key neurotransmitters including acetylcholine, dopamine, glutamate and gamma-aminobutyric acid [2–4]; reviewed in [5]. Given its widespread distribution and influence upon multiple neurotransmitter systems, H₃ antagonists are promising clinical

candidates for the treatment of age-related dementias, such as DLB [6–8].

There are indications that histamine deficits are present in dementias, such as Alzheimer's Disease (AD), however it is unknown whether these are specific to certain brain regions, changes in histamine receptor numbers, or are specific for AD amongst other neurodegenerative disorders. The importance of the histaminergic system in AD is difficult to assess due to a number of conflicting reports. For example, histamine levels in AD brains have been reported to be increased in temporal and frontal cortex, basal ganglia and hippocampus [9]. However, other studies have shown decreases in histamine content in the hypothalamus, hippocampus and temporal cortex [10,11]. Histaminergic cell bodies are also located in the TMN, where neurofibrillary tangles (NFTs) are also found. NFTs are particularly concentrated in the region containing histaminergic perikarya compared with surrounding areas [12,13] and together with cholinergic basal forebrain nuclei, the TMN has been described as an early affected subcortical nucleus for the presence of NFT [14]. The number of histaminergic cell bodies in the TMN was shown to be similar to that of normal brains [12]. In contrast, another group showed a significant reduction in large-sized histamine containing neurons in the TMN where numerous NFTs were found, indicative of a central histaminergic dysfunction [13]. Histamine decarboxylase (HDC) activity, also a common marker of

Abbreviations: DLB, Dementia with Lewy Bodies; AD, Alzheimer's Disease; ADHD, attention deficit hyperactivity disorder; NFTs, neurofibrillary tangles; PM, post mortem delay; RαMHA, R-α-methylhistamine; MMSE, Mini Mental State Examination; UPDRS, Unified Parkinson Disease Rating Scale; MCID, Microcomputer Imaging Device.

* Corresponding author at: Department of Biosciences, University of Durham, South Road, Durham, DH13LE, UK.

E-mail address: paul.chazot@durham.ac.uk (P.L. Chazot).

<http://dx.doi.org/10.1016/j.phrs.2016.08.034>

1043-6618/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

the histaminergic system, has been shown to be decreased in AD compared with elderly controls [15]. Whilst there are conflicting data about the histamine content in the brain of AD patients, one recent study using a highly selective H₃R ligand had shown the level of H₃R expression to be unaltered in the late stages of human AD compared to age matched controls, as well as in TASTPM mice (a mouse model of AD) compared with wild type mice [6,16].

Understanding the molecular structure of the H₃R has increased considerably and a number of H₃R antagonists have been identified and a few (pitolisant and GSK189254) have entered advanced clinical development focusing on narcolepsy, cognitive and psychotic disorders [8,18,19]. The histaminergic system innervates several structures that are known to be involved in cognition such as the basal forebrain, cerebral cortex, cingulate cortex, amygdala and thalamus [20]. High levels of H₃R have been shown to be expressed in the cerebral cortex [21], which is densely innervated by cholinergic neurons. In neuropsychiatric disorders such as AD, attention deficit hyperactivity disorder (ADHD) and schizophrenia, cognitive deficits play a major role in the disease [22]. Increased brain histamine is also positively correlated with age and may play a role in decreasing acetylcholine uptake [23]. It is thought that H₃R antagonists may be able to prevent the reduction in acetylcholine through its heteroreceptor characteristic [24–26]. H₃Rs are also highly expressed in the basal ganglia in both rodent and human brains [27–29].

Ligand autoradiography is a very useful technique to define the topology and quantify receptors in post-mortem brain slices. GSK189254 is derived from a novel benzazepine series of H₃R antagonists [6] that are structurally distinct from other recently described non-imidazole H₃R antagonists. GSK18925 has been shown to significantly improve performance of rats in diverse cognition paradigms, including passive avoidance, water maze, object recognition and attentional set shift [4,5]. The data thus far for H₃R antagonists point to a possible therapeutic potential for diseases where cognitive deficits are already present such as AD and other dementias, including DLB. These complex brain diseases also display multiple symptoms in addition to dementia which may be targeted through the histaminergic system. In this present study, [³H] GSK189254 was utilised to quantify levels of cortical and basal ganglia H₃Rs in normal human aged post-mortem brains, and in a series of DLB and AD cases (the latter for comparative purposes) with detailed connected clinical information.

2. Materials & methods

2.1. Determining the working concentration of [³H] GSK189254 for autoradiography

Saturation binding assays using [³H] GSK189254 were performed essentially as described previously [6], in 50 mM Tris-HCl, pH 7.7 containing 5 mM EDTA and a concentration range of 0.01–8 nM for radioligand. Non-specific binding was determined using 1 μ M R- α -methylhistamine (R α MeH). The assay was terminated by rapid filtration through a Whatman GF/B filters pre-soaked in 10 mM sodium phosphate dibasic pH 7.4, which were washed (3 \times 3 ml) using iced cold 10 mM sodium phosphate dibasic pH 7.4, using a Brandell 24-place cell harvester.

[³H] GSK189254 bound selectively to the hH₃R vs hH₄R, and the two major hH₃R isoforms, namely hH₃ 445 and hH₃ 365, transiently expressed in HEK293 cells [6], displayed very similar K_D values of 0.16 \pm 0.04 and 0.24 \pm 0.07 nM, respectively (Supplementary Fig. 1). The concentration of radioligand used was, therefore, selected as approximately 2 \times mean K_D to ensure that each autoradiography run detected at least 65% of available receptor binding sites.

2.2. Human case details and diagnostic criteria

All human brain tissue were obtained from Newcastle Brain Tissue Resource Bank LREC (Newcastle and Tyneside) with full ethical approval (2002/295). Frozen tissue was collected at autopsy and 1 cm coronal slices from the left hemisphere were snap frozen in liquid Arcton (ICI) and stored at -70°C . The sections were then stored at -80°C . Prior to sectioning, tissue slices were warmed to 15°C and blocks containing the striatum were sub-dissected and mounted onto cryostat chucks with 8% carboxymethylcellulose. Coronal sections were cryostat sectioned at a thickness of 20 μ m using a Brights OTF cryostat onto Vectabond-coated glass slides, air dried for 1–2 h and stored at -80°C prior to receptor autoradiography. The right hemisphere was used for histopathological examination, following formalin fixation and paraffin embedding. Cortical and hippocampal neurofibrillary tangles were demonstrated using a modification of Palmgren's silver technique [30] and the von Braunmühl silver impregnation technique [31] was used to identify senile plaques in 25 μ m thick frozen sections cut from tissue blocks adjacent to those taken for paraffin processing. Counts of NFTs and neuritic plaque number were made from fields across the entire cortical ribbon, as described in [32]. Lewy-bodies in the substantia nigra were visualised by the use of haematoxylin and eosin staining, cortical Lewy-bodies and dystrophic neuritis were detected using ubiquitin immunohistochemistry on 5 μ m thick paraffin embedded sections. Neurons in the substantia nigra were quantified following cresyl fast violet staining of 20 μ m thick paraffin sections.

Control cases had no history of psychiatric or neurological disorder and had no neuropathological indications of Lewy-body disease (DLB) or any other neurological disorder. DLB cases were clinically diagnosed by the presence of a progressive cognitive impairment seen in conjunction with at least two of the following symptoms: recurrent visual hallucinations; fluctuating cognition with pronounced variations in attention and alertness; spontaneous motor features of parkinsonism [33]. DLB cases were distinguished from AD by the presence of brain stem and cortical Lewy-bodies, Lewy neurites in the CA2/3 and endplate segments of the hippocampus [33], and by lower or moderate Alzheimer-type pathology with fewer NFT than found in AD.

2.3. Human cases used

The 43 cases selected for this study were cut at the level of the striatum (caudate nucleus and putamen) corresponding to coronal brain levels 9–15 using the Coronal Map of Brodmann Areas in the human Brain [34]. Of the 43 cases, 12 were control cases, 16 DLB cases and 15 AD cases (Table 1). For each case 5 replicates were used to measure 3 total and 2 non-specific radioligand binding.

Summary of the 43 human cases chosen for the study. PM delay = post mortem delay, that is, time between death and freezing of the tissue to allow for post-mortem examination.

No significant differences were seen with age or PM delay in these cases ($p > 0.05$). No gross significant differences were seen between the male and female cases in respective groups ($p > 0.05$) (not shown).

2.4. In vitro autoradiography of human brain tissue using [³H] GSK189254

The autoradiography method used was essentially as described previously [6]. In brief, human brain sections were left to equilibrate to room temperature for 1 h before the protocol commenced. Human sections were incubated in (50 mM Tris, 5 mM EDTA pH 7.7) containing 2 \times K_D (approximately 0.5 nM) [³H] GSK189254 (specific activity = 81 Ci/mmol, stored at -20°C , gift from Dr Medhurst, GSK, Harlow, UK) for 1 h at RT, until equilibrium is reached. Non-

Table 1
Summary of 43 human cases.

	n =			Age (years)			PM Delay (hours)		
	Total	Females	Males	Range	Mean	SD	Range	Mean	SD
Control	12	7	5	70–91	80.92	6.97	10–96	42	22.44
DLB	16	8	8	64–87	77.13	7.19	4–60	31.56	18.18
AD	15	9	6	74–91	83.27	4.53	4–82	33.40	21.69

Summary of the 43 human cases chosen for the study. PM delay = post mortem delay, that is, time between death and freezing of the tissue to allow for post-mortem examination.

specific binding was defined using 10 μ M unlabelled α MHA. The reaction was terminated by five 3 min washes in 50 mM Tris, 5 mM MgCl pH 7.7, at 4 °C and a final wash in dH₂O at 4 °C. Sections were left to dry in a stream of cold air for 1–2 h. The sections were then transferred to X-ray cassettes, each including tritium autoradiographical microscale as calibration standards, and exposed against tritium-sensitive hyperfilm for 6 weeks at 4 °C. The exposed films were then developed in D-19 developer (Kodak, UK) for 5 min at RT, fixed for 6 min in Unifix (Kodak, UK), washed under running water for 20 min and air-dried.

2.5. Image analysis

The resulting brain images on the film were captured using a Dage 72 MTI CCD72S video camera and were quantitatively analysed by computer-assisted densitometry using Microcomputer Imaging Device (MCID Elite) version 7.0 software from imaging research Inc., Ontario, Canada. The radioactive Tritium standards were used to calculate a standard curve for each autoradiogram, which allowed the conversion from optical density values to units of concentrations for each brain region analysed. Non-specific binding tissue sections were present on the same film as each of the corresponding total binding tissue sections for the same case. Specific binding was determined by subtracting mean non-specific binding from mean total binding. Brain structures were identified by reference to the atlas of the Human Brain [34] and the mean and standard deviations for each brain structure in each section were calculated. Inter-assay variability was reduced by using ligand concentrations that were at least twice the ligand affinity, using ligand from the same batch for each autoradiographical run, and by standardising each film using calibration microscales. All sections were then re-analysed and results confirmed by digital autoradiography using a Beta-Imager 2000 instrument (Biospace, Paris, France), radioactivity was measured by counting the number of β particles from delineated areas and the results are expressed as mean specific binding counts per minute per square millimetre (cpm/mm²; n = 12–16 cases per group).

2.6. Symptom analysis

2.6.1. The mini mental state examination (MMSE)

The MMSE, validated and widely used since its creation in 1975, is an effective tool for assessing cognitive mental status. The MMSE is used to detect cognitive impairment and monitor response to treatment. It is an eleven question test covering five areas of cognitive function: orientation, attention/calculation, recall and language, and the ability to follow simple verbal and written commands [35]. A score of 23 or below, from a possible 30 is indicative of cognitive impairment. The test is effective but does have limitations, for example, patients who are hearing and visually impaired or who have low English literacy, or with communication disorders may perform poorly even when cognitively intact [35]. The test provides a total score that places the individual on a scale of cognitive function. The values used in this were those taken at the last assessment before death of the patient.

2.6.2. Unified Parkinson disease rating scale (UPDRS)

The UPDRS is a rating tool to follow the longitudinal course of PD. It is made up of the 1) Mentation, Behaviour and Mood, 2) Activities of Daily Living (ADL) and 3) Motor sections. These are evaluated by interview. Some sections require multiple grades assigned to each extremity. A total of 199 points are possible, where 199 represent the worst (total) disability, and 0 represents no disability [36]. The values used in this study were those taken at the last assessment before death of the patient.

Estimated lines of best fit for MMSE and UPDRS correlations were produced using GraphPad Prism and are represented on each graph, indicating any changes in binding levels in each tissue with increasing clinical score. The significance of the regression was determined from the generated p value, where $p \leq 0.05$ was considered to show a significant linear relationship between clinical score and binding level.

2.6.3. Other symptom analysis

Data relating to depression, delusions, dementia and visual hallucinations experienced by each subject in life were also studied. The severity of the symptoms experienced were measured on the following scale, 0 = none, 1 = mild, 2 = severe, and are indicative of the last assessment before death of the subject. In each case and in each tissue investigated, attempts were made to correlate the specific binding levels of [³H] GSK189254 data with a range of relevant clinical data scores. The depression, delusion and visual hallucination scores were displayed: 0 no symptoms and 1+ showing symptoms, giving the mean score \pm SD against binding levels in cpm/mm².

2.7. Statistical analysis

Statistical analysis performed involved correlation analysis and students unpaired t -test, to analyse individual regions of the brain. Graphs and one-way ANOVA with appropriate post-hoc test were constructed using GraphPad Prism version 4. Statistical significance was set at $p < 0.05$.

3. Results

3.1. Human H₃R pharmacology of [³H] GSK189254

The selectivity of [³H] GSK189254 for the human H₃R 445 in comparison to the closely related human H₄R 390 subtype was investigated. No significant binding was observed for the hH₄ receptor (Supplementary Fig. 1) Moreover, very similar K_d values (ca. 0.3 nM) for [³H] GSK189254 were observed with two of the most common, in cortical-striatal regions, human H₃R isoforms, H₃R 445 and H₃R 365 expressed alone or in combination in HEK293 cells (Supplementary Fig. 1). A representative digital photographic exemplar of specific [³H] GSK189254 binding shows the high levels of specific binding in the human brain slice. Very low non-specific binding (<5%) was achieved with the methodology utilised in this study. High binding levels were detected in various cortical (insular, anterior cingulate) and striatal (caudate, putamen, globus pallidus,

nucleus accumbens) regions (Supplementary Fig. 1) all relevant to symptomology of DLB.

3.2. Age-dependence of [^3H] GSK189254 binding in control and dementias

DLB cases were first examined for [^3H] GSK189254 binding levels in the various cortical and striatal brain regions spanning an age range of 60–80 years. There were no significant age-dependent changes in all brain regions analysed although individual variation was clear ($p \geq 0.1$ in all areas) (Fig. 1). A similar lack of change was observed in both control and AD cases over the age-range explored (not shown).

3.3. [^3H] GSK189254 binding levels in control and dementia cases

As there were no clear changes in [^3H] GSK189254 binding levels across the age-range, the data sets were pooled and a comparison made between controls and the two dementias. No significant differences were observed in the mean binding densities of [^3H] GSK189254 binding in all brain regions analysed (Fig. 2). The data were further analysed for gender differences (**not shown**), similar levels of binding was seen in both female and male cohorts in all brain regions, apart from minor changes in the globus pallidus, indicating little or no evidence for gender bias.

3.4. Correlation of [^3H] GSK189254 binding levels to cognitive and motor deficits

The clinical data corresponding to DLB and AD cases summarised in Table 1 were further analysed to determine if there were any correlation between [^3H] GSK189254 binding and MMSE (mini mental state examination) (Fig. 3) and UPDRS scores (Unified Parkinson disease rating scale) (Fig. 4). There was no significant correlation in the binding densities of [^3H] GSK189254 with MMSE score ($p \geq 0.5$) in all areas in DLB cases. There was also no significant correlation in the binding densities of [^3H] GSK189254 with MMSE score in AD cases analysed in parallel ($p \geq 0.2$ in all areas) (Supplementary Fig. 2).

Moreover, there were also no significant differences in the binding densities of [^3H] GSK189254 with increased UPDRS score in DLB (Fig. 4) and AD cases (Supplementary Fig. 3).

3.5. Correlation of [^3H] GSK189254 binding levels to affective and psychotic deficits

In many cases investigated, clinical information relating to depression and psychosis symptoms were recorded. There were no significant differences between the H₃R binding densities in DLB (Fig. 5) and AD cases (Supplementary Fig. 3), with and without depression in all brain structures investigated.

Similarly, there were no significant differences between the H₃R binding densities in DLB cases with and without severe delusions, except in the globus pallidus where a significant increase in H₃R binding was observed in cases with severe delusions ($p < 0.01$) (Fig. 6).




Fig. 1. Age-dependent specific binding of [^3H] GSK189254 in DLB cases ($n = 16$) in caudate, putamen, anterior cingulate cortex, insular cortex, nucleus accumbens and globus pallidus. No significant change in [^3H] GSK189254 binding levels was seen with the brain structures investigated ($n =$ number of individual patient cases).




Fig. 2. [³H] GSK189254 specific binding (cpm/mm²) densities (mean ± SEM for n individual patient cases) for pooled Control, DLB and AD cases for (A) Caudate, (B) Putamen, (C) Cingulate cortex, (D) Insular cortex, (E) external Globus Pallidus, (F) internal Globus Pallidus. No significant differences in binding levels was observed in the brain structures investigated.

There were no significant differences between the H₃R binding densities and severity of visual hallucinations, although there is an increased H₃R binding in the globus pallidus associated with severe visual hallucinations.

Overall H₃R binding in both AD and DLB cases does not show any correlation with MMSE, UPDRS, and depression symptoms in cortical or striatal structures in the human CNS. In contrast, increased H₃R binding positively correlated with increased severity of psy-

chotic symptoms (delusions and visual hallucinations) in the globus pallidus in both DLB Figs. 6 and 7 and AD (Supplementary Fig. 4 and 5) cases.

4. Discussion and conclusion

The high affinity and selective H₃R antagonist/inverse agonist [³H] GSK189254 provides an ideal tool to visualise and allow quan-




Fig. 3. MMSE Scale against specific binding cpm/mm² of $[^3\text{H}]$ GSK189254 in DLB cases in (A) Caudate, (B) Putamen, (C) Cingulate cortex, (D) Insular cortex, (E) External globus pallidus, (F) Internal globus pallidus. No significant relationship was seen with the brain structures investigated (each point is an individual DLB patient case).

tification of the human histamine H₃R. The ligand displays a high affinity for two of the most common human H₃R isoforms, and also very low non-specific binding properties, which makes it an ideal ligand autoradiographical tool and a vast improvement on previously utilised radioligands (e.g. α Methylhistamine and clobenpropit [37]). A range of brain structures implicated in the characteristic symptoms of DLB and AD were investigated. The striatum has a well-known role in planning and modulation of movement pathways, but is also involved in a variety of other cognitive processes involving executive function. The cerebral cortex is involved in many complex brain functions including memory processing, attention, perceptual awareness, language and consciousness. More specifically, the anterior cingulate cortex and globus pallidus are thought to be major neuroanatomical interface between emotion and cognition, and the insular cortex is believed

to process convergent information to produce an emotionally relevant context for sensory experience. The main focus of this present study was to determine any changes in the H₃R in relation to age and gender in control, DLB and AD cases, and relationship to specific symptoms displayed by the individuals. Several lines of evidence suggest that manipulation of the histamine system may alleviate some of the clinical symptoms of AD and DLB. H₃R blockade with antagonist/inverse agonists results in the up-regulation of several neurotransmitters which have been shown to have positive effects upon cognitive deficits in several animal models of dementia (reviewed in [8] and [11]).

Previous ligand autoradiography studies using less selective H₃R radioligands have reported high H₃R densities in the internal and external segments of the globus pallidus, caudate, putamen and nucleus accumbens with moderate levels in the anterior cin-




Fig. 4. Unified Parkinson Disease Rating Scale against specific binding cpm/mm² of [³H] GSK189254 in DLB cases in (A) Caudate, (B) Putamen, (C) Cingulate cortex, (D) Insular cortex, (E) External globus pallidus, (F) Internal globus pallidus. Each point is an individual DLB patient case.

gulate and insular cortices [38,39] which concurs well with the present study. Furthermore, in this present study, no significant differences were observed with age although this was only over the restricted 60–80 age range; changes prior to 60 years of age may have occurred and require further investigation. Using [³H] clonpropit it was also reported that no significant age-related changes in H₃R expression in the basal ganglia occurred in normal ageing, nor did receptor density differ significantly between male and female cases [37]. Therefore, H₃R levels does not appear to be grossly altered in the latter stages of normal aging.

H₃R binding levels were next determined in DLB to establish whether disease state alters receptor levels. H₃R binding densities in both cortical and striatal regions in DLB human cases showed no significant differences in ligand binding with age, which supported

previously published data suggesting that the H₃R is preserved in two common age-related dementias, namely AD and vascular dementias, in other cortical and limbic regions [40]. This was also confirmed in this present study with different AD cases and different cortical brain structures. Overall, these data suggest that there is no gross decline in H₃R population between control and disease cases, providing further evidence for H₃R preservation across a range of neurodegenerative diseases. Preclinical trials have already alluded to the prospect of H₃R antagonists as a treatment for cognitive impairment. We provide further evidence showing preservation of H₃R in many cortical and striatal brain regions in AD but also in DLB, promoting the H₃R as a viable general target in treating a range of human dementias. This has yet to be realised in the clinic.




Fig. 5. Correlation of Depression score against specific binding cpm/mm² of [³H] GSK189254 in DLB cases in (G) Nucleus Accumbens, (H) combined Globus Pallidus. No significant correlation was observed between [³H] GSK189254 binding levels and depression scores in all brain structures investigated. N = number of individual Disease cases.

The data set produced was further interrogated with respect to selective symptoms present in the dementia cohorts prior to death and relationship to H₃R expression. The H₃R binding levels were correlated with symptom severity scores from various validated clinical tests. There was no correlation between H₃R binding levels and MMSE or UPDRS scores in both DLB and AD cases, indicating that the H₃R expression levels in the brain structures investigated do not influence the severity of cognitive and mobility impairment, respectively. The latter is in contrast with reported higher H₃R binding levels observed in the motor loop structures, substantia nigra and ventral striatum in PD animal studies (e.g. [41]). These translational discrepancies highlight the importance of promoting more human postmortem and live imaging brain studies. There was a modest overall increase in H₃R binding sites with decrease in MMSE score indicative of cognitive function. The increase in H₃R binding maybe acting as a compensatory mechanism to counteract changes

seen elsewhere in the histaminergic system in severe AD and DLB such as a decrease in frontal cortex H₁R in AD [42], and reduced H₂R expression in the hippocampus in both AD and DLB cases [35]. The functional consequence of increased H₃R density could be a further decrease in cognitive neurotransmitters and hence further exacerbation of cognitive deficits, and so would not be a positive compensatory effect. Alternatively, the increase in H₃R binding in brains of individuals with more severe dementia could be simply related to loss of cholinergic neurons. Loss of cholinergic neurons in the basal forebrain is one of the most prominent and consistent events occurring in AD [43]. These data support previous literature indicating that higher H₃R binding correlated with more severe dementia (MMSE) in AD [16], but this was more pronounced in the pre-frontal cortex.

Now to consider other symptoms present in many of the cases studied. There was no correlation between H₃R binding and sever-




Fig. 6. Correlation of delusion score against specific binding cpm/mm² of [³H] GSK189254 in DLB cases in (G) Nucleus Accumbens, (H) combined Globus Pallidus. A significant elevation of [³H] GSK189254 binding sites in the globus pallidus was observed in DLB cases with severe delusion compared to cases lacking delusions ($p < 0.05$). No significant relationship was observed with the other brain structures investigated. (n = number of individual patient cases).

ity of depression in DLB and AD cases, suggesting that the H₃R does not play a major role in depression symptoms associated with AD and DLB. This is consistent with recent studies in depressed and bipolar patients [44,45]. This lack of correlation held for most brains studied herein in terms of the psychotic symptoms. However, an interesting exception was the globus pallidus, where H₃R binding levels positively correlated with presence of significant psychotic symptoms, particularly levels of delusion and, to a lesser extent visual hallucinations, in both DLB and AD cases. DLB cases with moderate to high delusion and visual hallucination scores displayed approximately 40% and 22% higher globus pallidus H₃R binding

densities, respectively, in comparison to cases lacking such psychotic symptoms. A similar trend was present in AD cases with moderate to high delusion and visual hallucination scores displayed approximately 37% and 14% higher H₃R binding densities, respectively in comparison to cases lacking such psychotic symptoms. It has been previously reported that the globus pallidus is spared of pathology in Lewy body diseases, DLB and PDD [46]. However, the volume of the human globus pallidus has also been positively correlated with the severity of global psychotic symptoms, as measured by both the Scale for the Assessment of Negative Symptoms and Positive Symptoms [47], which may account for this appar-




Fig. 7. Visual hallucination score against specific binding cpm/mm² of [³H] GSK189254 in DLB cases in (C) Nucleus Accumbens, (H) combined Globus Pallidus. A significant elevation of [³H] GSK189254 in the globus pallidus was observed in DLB cases with visual hallucinations ($p < 0.05$). No significant relationship was seen with the other brain structures investigated (n = number of individual patient cases).

ent increase in the H₃R. This finding was more profound in the DLB cases than AD cases and this is to be expected since DLB cases have generally more pronounced psychotic symptomatology than AD cases. H₃R expression has been shown to be altered in patients with Schizophrenia and is thought to be involved in the underlying neuropathology [48]. The study showed significantly higher histamine H₃R radioligand binding sites in the prefrontal cortex of the schizophrenic group and bipolar subjects with psychotic symptoms, and higher H₃R binding correlated with psychotic symptoms, as seen in this present study [48]. H₃R in the human prefrontal cortex is thought to be involved in the modulation of cognition and emotional behaviours, and this is supported by findings in animals that H₃R antagonists enhance prepulse inhibition and cognitive performance [49–51]. Early promise with pitolisant, a H₃R antag-

onist/inverse agonist for the psychotic symptoms in schizophrenic patients [18,19], has not been confirmed with another H₃R antagonist, ABT-288 [17], with a distinct pharmacokinetic profile. Such studies are still lacking, however, in Lewy body dementia patients, DLB and PDD. The main limitation common to this type of study lies in the relatively small number of cases investigated. The quality of the case tissue and respective clinical information from a leading DLB brain bank centre is a strength of this study, but naturally, further studies are required to confirm these interesting findings utilizing cases from other international brain banks. Furthermore, future studies are also required to probe other key brain structures implicated in psychotic symptoms in DLB and PDD cases.

In conclusion, the key novel findings were the general preservation or elevated levels of the H₃R in both normal ageing humans and

in the two major human dementia disorders in a variety of cortical and striatal brain structures. This study reports, for the first time, the globus pallidus as a potential new player in the neuropathology of Dementias, particularly those with psychotic symptomologies such as DLB, and as a potentially new target for histaminergic clinical manipulation.

Conflict of interest

None.

Acknowledgements

This article is dedicated to the memory of Sheila Chazot. We would like to thank Dr Margaret Piggott (formally lead scientist at Newcastle University and the Newcastle brain bank, and Dr Andrew Medhurst (formally Lead Scientist at GSK, Harlow, UK) for support, advice and radioligand. This study was funded by a BBSRC/GSK (UK) CASE award (NL) and Parkinson's UK.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.phrs.2016.08.034>.

References

- [1] I.G. McKeith, D. Galasko, K. Kosaka, E.K. Perry, D.W. Dickson, L.A. Hansen, D.P. Salmon, J. Lowe, S.S. Mirra, E.J. Byrne, G. Lennox, N.P. Quinn, J.A. Edwardson, P.J. Ince, C. Bergerson, A. Burns, B.L. Miller, S. Lovestone, D. Collerton, E.N.H. Jansen, C. Ballard, R.A.I. de Vos, F.K. Wilcock, K.A. Jellinger, E.K. Perry, Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy-body (DLB): report on the consortium on DLB international workshop, *Neurology* 47 (1996) 113–124.
- [2] T.A. Esbenshade, G.B. Fox, M.D. Cowart, Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders, *Mol. Interv.* 6 (2006) 77–88.
- [3] P. Bonaventura, M. Letavic, C. Dugovic, S. Wilson, L. Aluisio, C. Pudiak, B. Lord, C. Mazur, F. Kamme, S. Nishino, N. Caruthers, T. Lovenberg, Histamine H3 receptor antagonists: from target identification to drug leads, *Biochem. Pharmacol.* 73 (2007) 1084–1096.
- [4] T.A. Esbenshade, K.E. Browman, R.S. Bitner, M. Strakhova, M.D. Cowart, J.D. Brioni, The histamine H3 receptor: an attractive target for the treatment of cognitive disorders, *Br. J. Pharmacol.* 154 (2008) 1166–1181.
- [5] P. Panula, P.L. Chazot, M. Cowart, R. Gutzmer, R. Leurs, W.L. Liu, H. Stark, R.L. Thurmond, H.L. Haas, *Pharmacol. Rev.* 67 (3) (2015) 601–655.
- [6] A.D. Medhurst, A.R. Atkins, K. Brackenborough, M.A. Briggs, A.R. Calver, J. Cilia, J.E. Cluderay, B. Crook, J.B. Davis, R.K. Davis, R.P. Davis, L.A. Dawson, A.G. Foley, J. Gartlon, M.I. Gonzalez, T. Heslop, W.D. Hirst, C. Jennings, D.N. Jones, L.P. Lacroix, A. Martyn, S. Ocieplka, A. Ray, C.M. Regan, J.C. Roberts, J. Schogger, E. Southam, T.O. Stean, B.K. Trail, N. Upton, G. Wadsworth, J.A. Wald, T. White, J. Witherington, M.L. Woolley, A. Worby, D.M. Wilson, GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models, *J. Pharmacol. Exp. Ther.* 321 (3) (2007) 1032–1045.
- [7] A.D. Medhurst, M.A. Briggs, G. Bruton, A.R. Calver, I. Chessell, B. Crook, Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats, *Biochem. Pharmacol.* 73 (2007) 1182–1194.
- [8] M. Cowart, R. Faghghi, M.P. Curtis, G.A. Gfesser, Y.L. Bennani, L.A. Black, L. Pan, K.C. Marsh, J.P. Sullivan, T.A. Esbenshade, G.B. Fox, A.A. Hancock, 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potentially enhance cognition and attention, *J. Med. Chem.* 48 (1) (2005) 38–55.
- [9] R. Cacabelos, A. Yamatodani, H. Niigawa, S. Hariguchi, K. Tada, T. Nishimura, Brain histamine in Alzheimer's disease, *Methods Find. Exp. Clin. Pharmacol.* 11 (1989) 353–360.
- [10] I.M. Mazurkiewicz-Kwilecki, S. Nsonwah, Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients, *Can. J. Physiol. Pharmacol.* 67 (1989) 75–78.
- [11] P. Panula, J. Rinne, K. Kuokkanen, K.S. Eriksson, T. Sallmen, H. Kalimo, M. Relja, Neuronal histamine deficit in Alzheimer's disease, *Neuroscience* 82 (1998) 993–997.
- [12] M.S. Airaksinen, K. Reinikainen, P. Riekkinen, Neurofibrillary tangles and histamine-containing neurons in Alzheimer hypothalamus, *Agents Actions* 33 (1–2) (1991) 104–107.
- [13] S. Nakamura, M. Takemura, K. Ohnishi, T. Suenaga, M. Nishimura, I. Akiyoshi, J. Kimura, T. Kimura, Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimer's disease, *Neurosci. Lett.* 151 (1993) 581–587.
- [14] H. Braak, E. Braak, Neuropathological staging of Alzheimer's related changes, *Acta Neuropathol. (Berl.)* 82 (1991) 239–259.
- [15] C. Schneider, D. Risser, L. Kirchner, E. Kitzmüller, N. Cairns, H. Prast, N. Singewald, G. Lubec, Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease, *Neurosci. Lett.* 222 (3) (1997) 183–186.
- [16] A.D. Medhurst, J.C. Roberts, J. Lee, C.P. Chen, S.H. Brown, S. Roman, M.K. Lai, Characterization of histamine H3 receptors in Alzheimer's disease brain and amyloid overexpressing TASTPM mice, *Br. J. Pharmacol.* 157 (1) (2009) 130–138.
- [17] G.M. Haig, E. Bain, W. Robieson, A.A. Othman, J. Baker, R.A. Lenz, A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia, *Schizophr. Bull.* 40 (6) (2014) 1433–1442.
- [18] J.C. Schwartz, The histamine H3 receptor: from discovery to clinical trials with pitolisant, *Br. J. Pharmacol.* 163 (4) (2011) 713–721.
- [19] J.C. Schwartz, J.M. Lecomte, Clinical trials with H3-receptor inverse agonists: what they tell us about the role of histamine in the human brain, *Neuropharmacology* (April (7)) (2016), pii: S0028-3908(16)30142-3.
- [20] P.L. Chazot, Therapeutic potential of histamine H3 receptor antagonists in dementias, *Drug News Perspect.* 23 (2) (2010) 99–103.
- [21] R.E. Brown, D.R. Stevens, H.L. Haas, The physiology of brain histamine, *Prog. Neurobiol.* 63 (6) (2011) 637–672.
- [22] H. Pollard, J. Moreau, S. Arrang, M.S. Airaksinen, A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas, *Neuroscience* 52 (1993) 169–189.
- [23] R. Leurs, C. Celanire, M. Wijnmans, P. Talaga, I.J.P. de Esch, Histamine H3 receptor antagonist reach out for the clinical, *Keynote Rev.* 10 (2005) 1613–1627.
- [24] G.D. Prell, J.K. Khandelwal, R.S. Burns, P.A. LeWitt, J.P. Green, Influence of age and gender on the levels of histamine metabolites and pro-methylimidazoleacetic acid in human cerebrospinal fluid, *Arch. Gerontol. Geriatr.* 12 (1) (1991) 1–12.
- [25] P. Blandina, M. Giorgetti, L. Bartolini, M. Cecchi, H. Timmerman, R. Leurs, G. Pepeu, M.G. Giovannini, Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats, *Br. J. Pharmacol.* 119 (1996) 1656–1664.
- [26] I. Cangioli, E. Baldi, P.F. Mannaioni, C. Bucherelli, P. Blandina, M.B. Passani, Activation of histaminergic H3 receptors in the rat basolateral amygdala improves expression of fear memory and enhances acetylcholine release, *Eur. J. Neurosci.* 16 (3) (2002) 521–528.
- [27] L. Bacciotini, M.B. Passani, L. Giovannelli, I. Cangioli, P.F. Mannaioni, W. Schunack, P. Blandina, Endogenous histamine in the medial septum-diagonal band complex increases the release of acetylcholine from the hippocampus: a dual-probe microdialysis study in the freely moving rat, *Eur. J. Neurosci.* 15 (10) (2002) 1669–1680.
- [28] C. Ferrada, S. Ferré, V. Casadó, A. Cortés, Z. Justinova, C. Barnes, E.I. Canela, S.R. Goldberg, R. Leurs, C. Lluís, R. Franco, Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function, *Neuropharmacology* 55 (2) (2008) 190–197.
- [29] O.V. Anichtchik, N. Peitsaro, J.O. Rinne, H. Kalimo, P. Panula, Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease, *Neurobiol. Dis.* 8 (2001) 707–716.
- [30] R.B. Cross, Demonstration of neurofibrillary tangles in paraffin sections: a quick and simple method using a modification of Palmgren's method, *Med. Lab. Sci.* 39 (1982) 299–301.
- [31] J.D. Bancroft, A. Stevens, Theory and Practice of Histological Techniques, 3rd ed., Churchill, Livingstone Edinburgh, 1990.
- [32] I.G. McKeith, D.W. Dickson, J. Lowe, M. Emre, J.T. O'Brien, H. Feldman, J. Cummings, J.E. Duda, C. Lippa, E.K. Perry, D. Aarsland, H. Arai, C.G. Ballard, B. Boeve, D.J. Burn, D. Costa, T. Del Ser, B. Dubois, D. Galasko, S. Gauthier, C.G. Goetz, E. Gomez-Tortosa, G. Halliday, L.A. Hansen, J. Hardy, T. Iwatsubo, R.N. Kalara, D. Kaufer, R.A. Kenny, A. Korczyn, K. Kosaka, V.M. Lee, A. Lees, I. Litvan, E. Londos, O.L. Lopez, S. Minoshima, Y. Mizuno, J.A. Molina, E.B. Mukaeova-Ladinska, F. Pasquier, R.H. Perry, J.B. Schulz, J.Q. Trojanowski, M. Yamada, Consortium on DLB, Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium, *Neurology* 65 (12) (2005) 1863–1872.
- [33] R.H. Perry, A guide to the cortical regions, in: G.W. Roberts, P.N. Leigh, D.R. Weinberger (Eds.), *Neuropsychiatric Disorders*, Wolfe, London, 1993, pp. 1.1–1.10.
- [34] J.K. Mai, Asseuer, G. Paxinos, Atlas of the Human Brain, Academic Press, San Diego, Calif, 1997.
- [35] M.F. Folstein, S. Folstein, P. McHugh, Mini mental state. A practical method for grading the cognitive state of patients for the clinician, *J. Psychiatr. Res.* 12 (3) (1975) 189–198.

- [36] C. Ramaker, J. Marinus, A.M. Stiggelbout, B.J. van Hilten, Systematic evaluation of rating scales for impairment and disability in Parkinson's disease, *Mov. Disord.* 7 (5) (2002) 867–876.
- [37] R.E. Goodchild, J.A. Court, I. Hobson, M.A. Piggott, R.H. Perry, P. Ince, E. Jaros, E.K. Perry, Distribution of histamine H₃-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases, *Eur. J. Neurosci.* 11 (2) (1999) 449–456.
- [38] M.I. Martinez-Mir, H. Pollard, J. Moreau, J.M. Arrang, M. Ruat, E. Traiffort, J.C. Schwartz, J.M. Palacios, Three histamine receptors (H₁, H₂ and H₃) visualized in the brain of human and non-human primates, *Brain Resolut.* 526 (1990) 322–327.
- [39] Y. Sheng, J.H. Lee, A.D. Medhurst, G.K. Wilcock, M. Esiri, P.T. Wong, C.P. Chen, M.K. Lai, Preservation of cortical histamine H₃ receptors in ischemic vascular and mixed dementias, *J. Neurol. Sci.* 315 (1–2) (2012) 110–114.
- [40] L. Shan, K. Bossers, U. Unmehopa, A.M. Bao, D.F. Swaab, Alterations in the histaminergic system in Alzheimer's disease: a postmortem study, *Neurobiol. Ageing* 33 (11) (2012) 2585–2598.
- [41] O.V. Anichtchik, M. Houtari, N. Peitsaro, J.W. Haycock, P.T. Mannisto, P. Panula, Modulation of histamine H₃ receptors in the brain of 6-hydroxydopamine-lesioned rats, *Eur. J. Neurosci.* 12 (11) (2000) 3823–3832.
- [42] M. Higuchi, K. Yanai, N. Okamura, K. Meguro, H. Arai, M. Itoh, R. Iwata, T. Ido, T. Watanabe, H. Sasaki, Histamine H₁ receptors in patients with Alzheimer's disease assessed by positron emission tomography, *Neuroscience* 99 (4) (2000) 721–729.
- [43] P.J. Whitehouse, D.L. Price, R.G. Struble, A.W. Clark, J.T. Coyle, M.R. Delon, Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain, *Science* 215 (4537) (1982) 1237–1239.
- [44] L. Shan, X.R. Qi, R. Balesar, D.F. Swaab, A.M. Bao, The human histaminergic system in neuropsychiatric disorders, *Trends Neurosci.* 38 (3) (2015) 167–177.
- [45] L. Shan, A.M. Bao, D.F. Swaab, Unaltered histaminergic system in depression: a postmortem study, *J. Affect. Disord.* 146 (2) (2013) 220–223.
- [46] R. Spinks, R.P. Nopoulos, J. Ward, R. Fuller, V.A. Magnotta, N.C. Andreasen, Globus pallidus volume is related to symptom severity in neuroleptic naive patients with schizophrenia, *Schizophr. Res.* 73 (2–3) (2005) 229–233.
- [47] X. Caseras, K.E. Tansey, S. Foley, D. Linden, Association between genetic risk scoring for schizophrenia and bipolar disorder with regional subcortical volumes, *Transl. Psychiatry* 5 (2015) e692.
- [48] C.Y. Jin, O. Anichtchik, P. Panula, Altered histamine H₃ receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases, *Br. J. Pharmacol.* 157 (1) (2009) 118–129.
- [49] G.B. Fox, J.B. Pan, T.A. Esbenshade, Y.L. Bennani, L.A. Black, R. Faghieh, A.A. Hancock, M.W. Decker, Effects of histamine H₃ receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup, *Behav. Brain Res.* 131 (2002) 151–161.
- [50] G.B. Fox, T.A. Esbenshade, J.B. Pan, R.J. Radek, K.M. Krueger, B.B. Yao, K.E. Browman, M.J. Buckley, M.E. Ballard, V.A. Komater, H. Miner, M. Zhang, R. Faghieh, L.E. Rueter, R.S. Bitner, K.U. Drescher, J. Wetter, K. Marsh, M. Lemaire, R.D. Porsolt, Y.L. Bennani, J.P. Sullivan, M.D. Cowart, M.W. Decker, A.A. Hancock, Pharmacological properties of ABT-239[4-(2-[(2R)-2-methylpyrrolidinyl]ethyl)-benzofuran-5-yl] benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H₃ receptor antagonist, *J. Pharmacol. Exp. Ther.* 313 (2005) 176–190.
- [51] K.E. Browman, V.A. Komater, P. Curzon, L.E. Rueter, A.A. Hancock, M.W. Decker, G.B. Fox, Enhancement of prepulse inhibition of startle in mice by the H₃ receptor antagonists thioperamide and ciproxifan, *Behav. Brain Res.* 153 (2004) 69–76.